The EASL Podcast collection includes educational podcasts and audio versions of digital EASL offerings. The ASK EASL Podcasts: Ongoing series of educational podcasts. EASL Studio: Your weekly hepatology broadcast news.
EASL Studio Podcast: JHEP Live: Should the compensated advanced chronic liver disease (cACLD) concept replace cirrhosis?
2 giorni fa
31:27The definition of cACLD is now strongly linked to care and research outcomes such as non invasive diagnosis, reversibility and prevention of decompensation. Thus, what space is left for the use of the old term cirrhosis in clinical practice and research?FacultyPaolo Angeli (Moderator)Guadalupe Garcia-Tsao (Faculty)Valérie Paradis (Faculty)Thomas Reiberger (Faculty)Related episodesEASL Studio S5E5: JHEP Live: the new nomenclature for SLD: a multidisciplinary evaluation and approachEASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclatureEASL Studio S4E4: JHEP Live: Is the term ‘decompensated cirrhosis’ outdated?All EASL Studio Podcasts are available on EASL Campus.
EASL Studio Podcast: World Cholangiocarcinoma Day: Highlighting guidelines and exploring the horizon beyond
45:35In this exclusive session, Thomas Berg and his panelists examine the intricate world of intrahepatic Cholangiocarcinoma (iCCA), following the publication of the EASL clinical practice guidelines on iCCA in 2023. This discussion aim at raising awareness and promoting a deeper understanding of this complex condition, while touching upon the topic of targeted therapies, highlighting the advancements and challenges that lie ahead.FacultyThomas Berg (Moderator)Katie Kelley (Faculty)Daniela Sia (Faculty)Juan Valle (Faculty)This episode is scheduled in honour of the World CCA Day (15 February) and the US CCA Awareness Month.Related episodesEASL Studio S5E13: Basics in decision-making for liver cancer treatmentEASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillanceEASL Studio S3E16: Liver cancer in 2022: Wrap-up & outlookEASL Studio S3E8: Transplanting patients with cancer – Is there a limit?All EASL Studio Podcasts are available on EASL Campus.
EASL Studio Podcast: How to stop recurrent bleeding due to small-intestinal angiodysplasia?
30:22The participants focus on the topic of managing recurrent bleeding due to small-intestinal angiodysplasia – a persistent challenge encountered by many hepatologists. Our panel explores effective treatments and interventions, including medications like bevacizumab and thalidomide, alongside the role of endoscopy in diagnosis and management.FacultyPierre-Emmanuel Rautou (Moderator)Virginia Hernández-Gea (Faculty)Patrick Kamath (Faculty)Wim Laleman (Faculty)Related episodes:EASL Studio S2E6: Should anticoagulants be given to patients with cirrhosis to improve outcomeAll EASL Studio Podcasts are available on EASL Campus.
EASL Studio Podcast: Do we solve MASLD by treating obesity?
33:29Our speakers explore the latest insights into the adipose tissue-liver axis, focusing on weight-reducing drugs’ current status and the crucial question of who should prescribe them and how efficacy should be monitored. They debate the implications of these drugs, their expected outcomes, and their integration into the toolkit of hepatologists.Don’t miss this opportunity to grasp the evolving dynamics between obesity treatment and MASLD management!FacultySven Francque (Moderator)Willem Pieter Brouwer (Faculty)Cyrielle Caussy (Faculty)Dimitris Papamargaritis (Faculty)This episode is scheduled following the United Kingdom’s National Obesity Awareness Week.Related episodes:EASL Studio S5E7: Why bother with diet and exercise when an injection will suffice?EASL Studio S4E8: The central role of alcohol and food policies on liver healthEASL Studio S2E2: Fats or carbs, who is the real villain?All EASL Studio Podcasts are available on EASL Campus.
EASL Studio Podcast: EASL Studio’s holiday reflection: A look back to leap forward
27:04Join us for a wrap-up of EASL Studio’s season and a preview of what is to come in 2024! In this special episode, we reminisce about the year’s top hepatology breakthroughs and controversies. This festive discussion highlights the best of the past while offering an exciting glimpse into the future of the evolving world of liver health.FacultyAleksander Krag (Moderator)Thomas Berg (Faculty)Ahmed Elsharkawy (Faculty)Debbie Shawcross (Faculty)All EASL Studio Podcasts are available on EASL Campus.
EASL Studio Podcast: Hepatic encephalopathy: Underdiagnosed and underestimated
35:56Hepatic encephalopathy (HE) is a common reversible complication of advanced liver disease characterised by a spectrum of neuropsychiatric abnormalities. Due to its insidious onset, most patients only seek treatment once complications develop, resulting in it being an underdiagnosed and underestimated condition.This EASL Studio episode, organised in collaboration with the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN), explores the patient journey and treatment options.FacultyDebbie Shawcross (Moderator)Christian Labenz (Faculty)Steve Rodrigues (Faculty)Dominique Thabut (Faculty)This EASL Studio is supported by Norgine. EASL has received no input from Norgine with regards to the content of this programme.Related episodeEASL Studio S2E7: JHEP Live on critical appraisal of classification, diagnosis and treatment of hepatic encephalopathyAll EASL Studio Podcasts are available on EASL Campus.
EASL Studio Podcast: Basics in decision-making for liver cancer treatment
33:03With cases of hepatocellular carcinoma on the rise and representing the end stage of many chronic liver diseases, the treatment of liver cancer has become one of the most dynamic areas in hepatology. The focus of this episode is on answering practical clinical questions, examining trial data, and sharing clinical insights that may be useful for decision-making in daily clinical practice.FacultyTom Lüdde (Moderator)Christoph Roderburg (Faculty)Anna Saborowski (Faculty)Arndt Vogel (Faculty)This EASL Studio is supported by AstraZeneca and Eisai. EASL has received no input from AstraZeneca or Eisai with regards to the content of this programme.Related episodesEASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillanceEASL Studio S3E16: Liver cancer in 2022: Wrap-up & outlookEASL Studio S3E8: Transplanting patients with cancer – Is there a limit?All EASL Studio Podcasts are available on EASL Campus.
EASL Studio Podcast: PSC and AIH overlap syndrome: does it actually exist?
29:44This episode explores key aspects of intriguing intersection of autoimmune liver diseases, such as their distinctive presentations in childhood and adulthood and the influence of inflammatory bowel disease on liver disease phenotypes. The speakers also examines the benefits and risks associated with immunosuppressive treatments in managing these complex conditions.FacultyPalak Trivedi (Moderator)Amanda Ricciuto (Faculty)Marianne Samyn (Faculty)Christoph Schramm (Faculty)This EASL Studio is supported by Chemomab Therapeutics. EASL has received no input from Chemomab Therapeutics with regards to the content of this programme.Related episodesEASL Studio S5E4: PBC: the itch we need to scratchEASL Studio from EASL Congress 2023: Challenges and opportunities for patients with PBC: Highlights from EASL Congress 2023EASL Studio S3E3: Primary biliary cholangitis: a look at the future landscape of therapy for patientsAll EASL Studio Podcasts are available on EASL Campus.
EASL Studio Podcast: The window hypothesis again, or just a closed window?
32:08The treatment of liver cirrhosis – currently based on symptomatic management of complications – has barely changed in last 20 years. In this episode, the experts discuss the use of statins, for which there is growing body of evidence of their beneficial effects in patients suffering with cirrhosis.FacultyThomas Reiberger (Moderator)Juan Gonzalez-Abraldes (Faculty)Elisa Pose (Faculty)Jonel Trebicka (Faculty)This EASL Studio is supported by Boehringer Ingelheim. EASL has received no input from Boehringer Ingelheim with regards to the content of this programme.Related episodesEASL Studio from EASL Congress 2023: Liver cirrhosis in 2023: Unmet needs and how to address themEASL Studio S4E17: Albumin in Cirrhosis: For all, some, or none?EASL Studio S4E4: JHEP Live: is the term ‘decompensated cirrhosis’ outdated?EASL Studio S3E12: Meeting the challenge of antimicrobial resistance (AMR) in cirrhosis: the invisible threat that lies withinAll EASL Studio Podcasts are available on EASL Campus.
EASL Studio Podcast: Why should diabetologists care about the liver?
36:50In this episode, participants tackle the relationship between metabolic dysfunction-associated steatotic liver diseases (MASLD) and type 2 diabetes (T2D), exploring their prevalence and the potential for more aggressive outcomes. Experts weigh in on the pressing questions of whether non-invasive test thresholds should be adapted for MASLD patients with T2D and which drugs should take precedence as first-line treatments for high-risk MASLD cases.FacultyZobair Younossi (Moderator)Laurent Castera (Faculty)Camilla Dalby Hansen (Faculty)Amalia Gastaldelli (Faculty)This episode is scheduled according to the international calendar for the World Diabetes Day (14 November).This EASL Studio is supported by Boehringer Ingelheim and Novo Nordisk. EASL has received no input from Boehringer Ingelheim or Novo Nordisk with regards to the content of this programme.Related episodes:EASL Studio S3E7: Bugs and the liver — the role of the gut microbiome in liver diseasesEASL Studio S2E2: Fats or carbs, who is the real villain?All EASL Studio Podcasts are available on EASL Campus.